Growth Hormone
CJC-1295 / Ipamorelin 5mg / 5mg
The classic secretagogue pairing. CJC-1295 raises baseline GH release, ipamorelin adds a clean pulse without touching cortisol or prolactin.
from$180
Catalogue
Growth Hormone
Secretagogues that work with the body's own GH axis. Nearly always run as a pairing.
Growth Hormone
CJC-1295 / Ipamorelin 10mg / 10mg
Double-strength CJC-1295 with ipamorelin — the long-block version of the standard pairing.
from$180
Growth Hormone
CJC-1295 without DAC 5mg
Also called Mod GRF (1-29). Short half-life, so it produces a pulse rather than a sustained elevation — the version most people pair with ipamorelin.
$140
Growth Hormone
CJC-1295 with DAC 5mg
The drug-affinity-complex version, with a far longer half-life. Fewer injections, a steadier baseline, less pulsatility.
$140
Growth Hormone
Ipamorelin 10mg
The most selective GH secretagogue in common use. Minimal effect on cortisol, prolactin or appetite, which is why it is the default pairing partner.
$155
Growth Hormone
Tesamorelin 5mg
A GHRH analogue with the most clinical data behind it in this category, particularly around visceral adipose tissue.
from$135
Growth Hormone
Tesamorelin 10mg
Double-strength tesamorelin for daily protocols that would otherwise burn through a 5 mg vial every ten days.
from$135
Growth Hormone
IGF-1 LR3 1mg
A long-arginine analogue of IGF-1 with reduced binding-protein affinity. An advanced compound — read the protocol notes before ordering.
$180
Research Use Only. All products sold by MaxSpan Peptides are supplied strictly for in vitro laboratory research by qualified professionals aged 21 or older. They are not intended for human or animal consumption, clinical use, diagnostic use, veterinary application, or any therapeutic purpose. Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. MaxSpan Peptides is a chemical supplier and is not a compounding pharmacy as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under Section 503B.